Arcutis Biotherapeutics, Inc. (ARQT)

Market Cap	1.07B
Revenue (ttm)	725,000
Net Income (ttm)	-310.77M
Shares Out	57.09M
EPS (ttm)	-4.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	542,493
Open	17.7
Previous Close	17.51
Day's Range	17.09 - 17.7
52-Week Range	13.59 - 27.4
Beta	0.44
Analysts	Buy
Price Target	56.21 (+224.0%)
Earnings Date	Nov 8, 2022

About ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ...

• Industry: Biotechnology
• IPO Date: Jan 31, 2020
• Employees: 147
• Stock Exchange: NASDAQ
• Ticker Symbol: ARQT

Analyst Forecast

According to 15 analysts, the average rating for ARQT stock is "Buy." The 12-month stock price forecast is 56.21, which is an increase of 223.98% from the latest price.

Price Target

$56.21

(223.98% upside)

Analyst Consensus: Buy